Clay Siegall giving cancer patients renewed Hope

Clay Siegall is one of the scientists who have shown relentless efforts in developing better cancer treatment methods. He is a multifaceted individual with immerse contributions that are not only confined to medicine, but he also runs very informative forums in various platforms. Clay’s personal blog is one of the channels he uses to share interesting insights from various fields. One of his posts highlights how human papillomavirus (HPV) vaccine has received a cold welcome, yet it has the capacity to prevent over 90 percent of cervical cancers and other cancer types as well as sexually transmitted diseases associated with HPV virus. Despite of the uncertainty surrounding this vaccine, more oncologists, clinicians and public heath activists are joining the bandwagon of supporting it as an effective cancer drug.


There is another intriguing post on the blog that expresses the possibility for the return of Tasmanian Tigers, which are believed to have gone extinct almost eight decades ago. The hope of marsupial return has forced researchers at Australia’s James Cook University into action with an aim of finding the truth about these animals.


In his quest to unearth better cancer treatments, Clay Siegall joined hands with other visionary entrepreneurs to found Seattle Genetics in 1998. As the company’s CEO, Chairman and president, Clay has helped the company into making impressive steps in discovering more cancer treatment drugs. Clay is the leadership force behind the development of antibody-drug conjugate (ADC). He also steered the company into developing ADCETRIS, a drug that has received positive reception for treating cancer.


SGN-CD33A is also a major drug under development. The drug is on clinical trial stage and it’s touted as a revolutionary drug in the treatment of AML patients. Apart from helping Seattle Genetics come up with amazing cancer drugs, Clay is the lead man in the company’s fund raising activities. In 2011, the company was able to raise over $330 million from private and public financing. Besides, the company has entered into strategic partnerships with GlaxoSmithKline, AbbVie, Genentech (Roche) and Pfizer, a move aimed at hastening the production of over 20 ADCs.


Leave a Reply